More on Watson Pharmaceuticals (WPI) Q3: net profit +24% to $172.3M. Revenue breakdown: generics +15%, brands +10%, distribution +44%. Increases FY guidance to $5.85-$5.95 for EPS and $5.9B for revenue vs consensus of $5.80 and $5.54B. For 2013, Watson expects adjusted EPS growth of 30%-40%. Has completed acquisition of Actavis, and will use that name from 2013.